Nanotechnology Now

Our NanoNews Digest Sponsors


Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Nanobiotix Selected to Present Data from NBTXR3 Clinical Trial at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO)

Abstract:
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announced that it has been selected by the American Society of Clinical Oncology (ASCO) to present data from its clinical trial evaluating NBTXR3 in advanced soft tissue sarcoma.

Nanobiotix Selected to Present Data from NBTXR3 Clinical Trial at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO)

Paris, France | Posted on April 2nd, 2014

The clinical trial will be presented during the congress session dedicated to sarcoma.

This year's ASCO will take place in Chicago from 31 May to 3 June, 2014. The Annual Meeting brings together more than 25,000 oncology professionals from a broad range of clinical research specialties.

The NBTXR3 study was selected from over 5,500 abstracts received by the Scientific Program Committee of ASCO for review.

Laurent Levy, CEO of Nanobiotix said: "We are honored that ASCO has invited us to present our NBTXR3 data in front of the international oncology community. This is an encouraging step for our team and our partners and we will continue to develop innovative therapies aimed to improve patient care in the fight against cancer."

####

About Nanobiotix
Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The Company’s first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy to provide a new, more efficient treatment for cancer patients. NanoXray products are compatible with current radiotherapy treatments and are meant to treat a wide variety of cancers via multiple routes of administration.

Nanobiotix’s lead product NBTXR3, based on NanoXray, is currently under clinical development for soft tissue sarcoma and locally advanced head and neck cancer. The Company, based in Paris, France, has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia.

Nanobiotix is listed on the regulated market of NYSE Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP).

Issued for and on behalf of Nanobiotix by Instinctif Partners.

Disclaimer

This press release and the information contained therein do not constitute an offer of securities for sale or any solicitation to purchase or subscribe for Nanobiotix's shares in any jurisdiction. The distribution of this press release in certain jurisdictions may constitute a breach of applicable laws and regulations. Therefore, individuals who are located in such jurisdictions where this press release is issued, published or distributed must seek information and comply with such laws and regulations.

For more information, please click here

Contacts:
Nanobiotix
Sarah Gaubert
Head of Communication
and Public Affairs
+33 (0)1 40 26 07 55


NewCap.
Financial communication
and investors relations
Louis-Victor Delouvrier / Emmanuel Huynh
+33 (0)1 44 71 98 53



Yucatan
Media relations (France)
Annie-Florence Loyer/ Nadčge Le Lezec
+33 (0)6 88 20 35 59



Instinctif Partners (formerly College Hill)
Media relations (Outside France)
Melanie Toyne Sewell / Donia Al Saffar / Katherine Lynch
+44 (0) 207 457 2020

Copyright © Nanobiotix

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

JPK’s NanoWizard AFM system is being used for cell studies in the Research Centre for Nanometer-scale Science & Advanced Materials at the Jagiellonian University in Krakow, Poland May 31st, 2016

Nanobiotix receives US$1m milestone payment from PharmaEngine: First patient injected with NBTXR3 in soft tissue sarcoma registration phase in Asia May 31st, 2016

GLOBALFOUNDRIES to Expand Presence in China with 300mm Fab in Chongqing: Company plans new manufacturing facility and additional design capabilities to serve customers in China May 31st, 2016

Nanobiotix establishes promising preclinical proof-of-concept in Immuno Oncology May 31st, 2016

Nanomedicine

JPK’s NanoWizard AFM system is being used for cell studies in the Research Centre for Nanometer-scale Science & Advanced Materials at the Jagiellonian University in Krakow, Poland May 31st, 2016

Nanobiotix receives US$1m milestone payment from PharmaEngine: First patient injected with NBTXR3 in soft tissue sarcoma registration phase in Asia May 31st, 2016

Nanobiotix establishes promising preclinical proof-of-concept in Immuno Oncology May 31st, 2016

Automating DNA origami opens door to many new uses: Like 3-D printing did for larger objects, method makes it easy to build nanoparticles out of DNA May 30th, 2016

Announcements

JPK’s NanoWizard AFM system is being used for cell studies in the Research Centre for Nanometer-scale Science & Advanced Materials at the Jagiellonian University in Krakow, Poland May 31st, 2016

Nanobiotix receives US$1m milestone payment from PharmaEngine: First patient injected with NBTXR3 in soft tissue sarcoma registration phase in Asia May 31st, 2016

GLOBALFOUNDRIES to Expand Presence in China with 300mm Fab in Chongqing: Company plans new manufacturing facility and additional design capabilities to serve customers in China May 31st, 2016

Nanobiotix establishes promising preclinical proof-of-concept in Immuno Oncology May 31st, 2016

Events/Classes

Novel gene therapy shows potential for lung repair in asthma May 18th, 2016

Arrowhead Pharmaceuticals' Preclinical Candidate ARC-LPA Achieves 98% Knockdown and Long Duration of Effect after Subcutaneous Administration May 10th, 2016

Nanometrics Announces Upcoming Investor Events May 10th, 2016

Oxford Instruments Asylum Research and McGill University Announce the McGill AFM Summer School and Workshop, May 12-13, 2016 May 4th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic